Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial

BACKGROUND: COX-2 inhibitors, such as celecoxib, and ubiquitin-proteasome pathway inhibitors, such as bortezomib, can down-regulate NF-κB, a transcription factor implicated in tumor growth. The objective of this study was to determine the maximum tolerated dose and dose-limiting toxicities of bortez...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayslip, John, Chaudhary, Uzair, Green, Mark, Meyer, Mario, Dunder, Steven, Sherman, Carol, Salzer, Shanta, Kraft, Andrew, Montero, Alberto J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2234426/
https://www.ncbi.nlm.nih.gov/pubmed/18053191
http://dx.doi.org/10.1186/1471-2407-7-221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2234426/
https://www.ncbi.nlm.nih.gov/pubmed/18053191
http://dx.doi.org/10.1186/1471-2407-7-221

Ejemplares similares